Open AccessThe effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trial
Author(s) -
Asaf Biber,
Geva Harmelin,
Dana Lev,
Li Ram,
Amit Shaham,
Ital Nemet,
Limor Kliker,
Oran Erster,
Michal Mandelboim,
Eli Schwartz
Publication year - 2022
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2022.07.003
Subject(s) - ivermectin , placebo , covid-19 , medicine , double blind , randomized controlled trial , viral load , virology , veterinary medicine , virus , pathology , alternative medicine , infectious disease (medical specialty) , disease
Ivermectin, an antiparasitic agent, also has antiviral properties. In this study, we aimed to assess whether ivermectin has anti-SARS-CoV-2 activity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom